These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 25646168)

  • 1. Healing of osteonecrosis of the jaw (ONJ) after discontinuation of denosumab in a patient with bone metastases of colorectal cancer: a case report and hypothesis.
    Ohga N; Yamazaki Y; Tsuboi K; Kitagawa Y
    Quintessence Int; 2015; 46(7):621-6. PubMed ID: 25646168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful conservative treatment of jaw osteonecrosis caused by denosumab in patients with multiple bone metastasis.
    Ohga N; Sato J; Asaka T; Morimoto M; Yamazaki Y; Kitagawa Y
    J Oral Sci; 2018; 60(1):159-162. PubMed ID: 29576576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
    You Tm; Lee KH; Lee SH; Park W
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review.
    de Oliveira CC; Brizeno LA; de Sousa FB; Mota MR; Alves AP
    Med Oral Patol Oral Cir Bucal; 2016 Jul; 21(4):e431-9. PubMed ID: 26827069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.
    Loyson T; Van Cann T; Schöffski P; Clement PM; Bechter O; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
    Acta Clin Belg; 2018 Apr; 73(2):100-109. PubMed ID: 28693379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteonecrosis of the jaw in patients transitioning from bisphosphonates to denosumab treatment for osteoporosis.
    Voss PJ; Steybe D; Poxleitner P; Schmelzeisen R; Munzenmayer C; Fuellgraf H; Stricker A; Semper-Hogg W
    Odontology; 2018 Oct; 106(4):469-480. PubMed ID: 29713913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab-related osteonecrosis of the jaw following non-surgical periodontal therapy: A case report.
    Diniz-Freitas M; Fernández-Feijoo J; Diz Dios P; Pousa X; Limeres J
    J Clin Periodontol; 2018 May; 45(5):570-577. PubMed ID: 29479739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I.
    Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P
    Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Osteonecrosis of the jaw in patients treated with denosumab: A multicenter case series.
    Aljohani S; Gaudin R; Weiser J; Tröltzsch M; Ehrenfeld M; Kaeppler G; Smeets R; Otto S
    J Craniomaxillofac Surg; 2018 Sep; 46(9):1515-1525. PubMed ID: 29983309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Denosumab-related osteonecrosis of the jaws: successful management with a conservative surgical approach.
    de Souza Póvoa RC; Marlierè DA; da Silveira HM; Pires FR
    Spec Care Dentist; 2016 Jul; 36(4):231-6. PubMed ID: 26859582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone.
    Shibahara T
    Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Osteonecrosis of the Jaw Under Denosumab Compared to Bisphosphonates in Patients With Osteoporosis.
    Everts-Graber J; Lehmann D; Burkard JP; Schaller B; Gahl B; Häuselmann H; Studer U; Ziswiler HR; Reichenbach S; Lehmann T
    J Bone Miner Res; 2022 Feb; 37(2):340-348. PubMed ID: 34787342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteonecrosis of the jaw in patients treated with denosumab for metastatic tumors to the bone: A series of thirteen patients.
    Owosho AA; Blanchard A; Levi L; Kadempour A; Rosenberg H; Yom SK; Farooki A; Fornier M; Huryn JM; Estilo CL
    J Craniomaxillofac Surg; 2016 Mar; 44(3):265-70. PubMed ID: 26782845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ.
    Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J;
    J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antiresorptive drugs on bony turnover in the jaw: denosumab compared with bisphosphonates.
    Ristow O; Gerngroß C; Schwaiger M; Hohlweg-Majert B; Kehl V; Jansen H; Hahnefeld L; Koerdt S; Otto S; Pautke C
    Br J Oral Maxillofac Surg; 2014 Apr; 52(4):308-13. PubMed ID: 24582013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteonecrosis of the jaw in a metastatic lung cancer patient with bone metastases undergoing pembrolizumab + denosumab combination therapy: Case report and literature review.
    Myoken Y; Fujita Y; Kawamoto K; Toratani S
    Oral Oncol; 2020 Dec; 111():104874. PubMed ID: 32605876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis.
    Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L
    Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study.
    Ristow O; Rückschloß T; Müller M; Berger M; Kargus S; Pautke C; Engel M; Hoffmann J; Freudlsperger C
    J Craniomaxillofac Surg; 2019 Mar; 47(3):491-499. PubMed ID: 30642734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials.
    Boquete-Castro A; Gómez-Moreno G; Calvo-Guirado JL; Aguilar-Salvatierra A; Delgado-Ruiz RA
    Clin Oral Implants Res; 2016 Mar; 27(3):367-75. PubMed ID: 25639776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Replacing zoledronic acid with denosumab is a risk factor for developing osteonecrosis of the jaw.
    Higuchi T; Soga Y; Muro M; Kajizono M; Kitamura Y; Sendo T; Sasaki A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 Jun; 125(6):547-551. PubMed ID: 29574058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.